SCM LifeScience Co

SCM LifeScience Co Financing Cash Flow

The Net Financing Cash Flow of SCM LifeScience Co (298060.KQ) as of Nov 19, 2026 is 2.96 B KRW. In the previous year, Net Financing Cash Flow was 16.73 B KRW — a change of -82.28% (lower).

Financing Cash Flow

2.96 BKRW

YoY

-82.28%

Last updated:

Net Financing Cash Flow of SCM LifeScience Co is 2024 2.96 B KRW. Net Financing Cash Flow of SCM LifeScience Co was 2023 16.73 B KRW. It decreases by -82.28% lower compared to the previous year.

The SCM LifeScience Co Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2017
88.59 M KRW
Jan 1, 2018
44.18 B KRW
Jan 1, 2019
11.72 B KRW
Jan 1, 2020
30.19 B KRW
Jan 1, 2021
425.29 M KRW
Jan 1, 2022
211.73 M KRW
Jan 1, 2023
16.73 B KRW
Jan 1, 2024
2.96 B KRW
The SCM LifeScience Co Financing Cash Flow history
YEARFinancing Cash FlowYoY
2.96 BKRW-82.28%
16.73 BKRW+7,799.33%
211.73 MKRW-50.21%
425.29 MKRW-98.59%
30.19 BKRW+157.62%
11.72 BKRW-73.48%
44.18 BKRW+49,772.06%
88.59 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCM LifeScience Co Stock analysis

What does SCM LifeScience Co do? SCM LifeScience Co Ltd is a biotechnology company headquartered in Incheon, South Korea. The company focuses on the development and production of cell therapy products, including adult stem cell therapies. It also engages in agency testing for cell production and quality assurance, as well as providing adult stem cell consulting services. Additionally, SCM LifeScience operates in the cosmetics and hair growth protein manufacturing sectors. The company has 55 full-time employees. SCM LifeScience completed its initial public offering (IPO) on June 17, 2020. Its stock is listed under the ticker 298060.KQ on the Korean stock exchange, with an ISIN code of KR7298060005. The company's website is http://www.scmlifescience.com/. SCM LifeScience operates within the healthcare sector, specifically within the biotechnology industry. It does not provide details on its founding year, specific product names, or financial figures beyond the IPO date and employee count. The company's activities span drug development for stem cell therapy, cell production testing, and manufacturing of related products. SCM LifeScience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCM LifeScience Co stock

Net Financing Cash Flow of SCM LifeScience Co is 2.96 B KRW in 2024.

Net Financing Cash Flow of SCM LifeScience Co changed from 16.73 B KRW to 2.96 B KRW, representing a -82.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow SCM LifeScience Co since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's SCM LifeScience Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — SCM LifeScience Co

All Key Metrics — SCM LifeScience Co